986 filings
Page 7 of 50
8-K
t6dg6
24 Nov 21
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma’s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
8:20am
8-K
y7pa euap
24 Nov 21
Entry into a Material Definitive Agreement
7:27am
8-K
aeyape
25 Oct 21
Seelos Therapeutics Presents a Poster on SLS-002 (Intranasal Racemic Ketamine) at the 2021 IASR/AFSP International Summit on Suicide Research
2:03pm
4
h9r5y0yn6b
2 Sep 21
SEELOS THERAPEUTICS / MARGARET DALESANDRO ownership change
4:08pm
3
06uqp8bp8
2 Sep 21
SEELOS THERAPEUTICS / MARGARET DALESANDRO ownership change
4:07pm
3
ec45pxvjkdsci3
2 Sep 21
SEELOS THERAPEUTICS / Michael Joseph Golembiewski ownership change
4:03pm
8-K
4u0 wkpv878
2 Sep 21
Seelos Therapeutics Announces Senior Management Appointments
4:01pm
8-K
qly7aym
17 Jun 21
Termination of a Material Definitive Agreement
4:14pm
8-K
fmwti1o06kr0t 3kg9
24 May 21
Seelos Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
4:15pm
8-K
l5i9e1fk6piifvgzecc
21 May 21
Material Modifications to Rights of Security Holders
4:29pm
424B5
zdchgnl
21 May 21
Prospectus supplement for primary offering
12:00am
8-K
dr9k3tth97 zj5gji70
21 May 21
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
12:00am
424B5
6sycquv27ixr jhn31pu
19 May 21
Prospectus supplement for primary offering
4:08pm
8-K
d7c3nnsv55ub9
17 May 21
Regulation FD Disclosure
6:12am
S-8
3bzkq8u4 0fc7m4z
30 Apr 21
Registration of securities for employees
12:00am
DEFA14A
708 5gfxbkppna4fxygs
26 Apr 21
Additional proxy soliciting materials
5:15pm